Protagonist Therapeutics

General Information

We are a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) to address significant unmet medical needs. Our primary focus is on developing first-in-class oral peptide drugs that specifically target the same biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, our oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery and the opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD).

Employees: 29
Founded: 2001
Contact Information
Address 521 Cottonwood Drive, Suite 100, Milpitas, California 95035, US
Phone Number (408) 649-7370
Web Address
View Prospectus: Protagonist Therapeutics
Financial Information
Market Cap $195.8mil
Revenues $0.0 mil (last 12 months)
Net Income $-24.0 mil (last 12 months)
IPO Profile
Symbol PTGX
Exchange NASDAQ
Shares (millions): 7.5
Price range $12.00 - $12.00
Est. $ Volume $90.0 mil
Manager / Joint Managers Leerink Partners/ Barclays/ BMO Capital Markets
CO-Managers -
Expected To Trade: 8/11/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change